Caroline Drukker evaluates the outcome prediction and clinical relevance of the 70-gene signature for locoregional and distant recurrence, its influence on risk assessment and adjuvant systemic therapy (AST) recommendations, and its additional value to established clinical guidelines used in breast cancer treatment. In addition, Drukker uses the 70-gene signature to gain better insight in the biological background of tumors detected in a population-based screening programme.
C.A. Drukker, Gene Signature for Risk Stratification and Treatment of Breast Cancer: Incorporating Tumor Biology in Clinical Decision-Making.
Prof. E.J.T. Rutgers
Prof. L.J. van ’t Veer (University of California, San Francisco)
Prof. S.C. Linn (UU)
Dr M.K. Schmidt (NKI-AvL)
This event is open to the public.